Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New trial combines HIV PrEP and STI prevention in one package for young men

NCT ID NCT07658976

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combined approach—offering HIV PrEP (pills or injections) and STI prevention (doxycycline after sex) along with smartphone tools—helps young men at high risk stay protected. About 400 men aged 18-29 who have sex with men will be followed for a year to see if the tools improve PrEP use and reduce infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HIV PrEP (F/TDF, F/TAF, or CAB-LA) and STI PEP (doxycycline)
What this could lead to
If successful, this approach could make it easier for young men to stick with HIV prevention and reduce sexually transmitted infections.
What could go wrong
This is a Phase 3 trial, but results depend on real-world adherence and may not apply to all populations. The mHealth tools may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 29 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men ages 18 - 29 years 2. Men who are in communities most affected by the HIV epidemic 3. Willing and able to provide informed consent 4. Reports having anal sex with men in the last 6 months 5. Have certain risk factors for HIV acquisition, defined as any of the following in the past 6 months: 1. Any condomless anal sex with a man; not including within a monogamous relationship with an HIV-negative partner or an HIV-positive partner who is virally suppressed 2. Reporting 2 or more male partners, regardless of condom use 3. Reporting gonorrhea, chlamydia, or syphilis diagnosis 4. Any stimulant use (e.g., cocaine, amphetamines) 6. Not on PrEP within the past 3 months due to participant choice 7. Interested in learning more about PrEP or starting PrEP 8. No evidence of HIV infection at Screening and Enrollment, based on the HIV testing algorithm 9. Owns an iOS or Android mobile phone and able to successfully download mobile apps and send and receive text messages 10. Must not share the mobile phone used for their participation in the study 11. Able to read and write Exclusion Criteria: 1. Participated in HPTN 113-01 2. Currently participating in another interventional trial of PrEP agents, or prior enrollment in studies of long-acting PrEP, including HPTN 083 3. Plans to move away from the study area within the next year 4. Currently on doxycycline for STI PEP 5. Has ever used CAB-LA or other long-acting PrEP agent 6. Tetracycline allergy 7. Prior diagnosis of HIV infection 8. Reactive HIV rapid test at Screening or reactive HIV Ag/Ab rapid test at Enrollment, regardless of subsequent HIV test results 9. Any other condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives would make the patient unsuitable for the study or unable/unwilling to comply with the study requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bronx Prevention Research Center CRS

    The Bronx, New York, 10451, United States

  • Fundacion Huesped CRS

    Buenos Aires, C1427CEA, Argentina

  • Instituto de Pesquisa Clinicaq Evandro Chagas CRS

    Manguinhos, Rio de Janeiro, 221045-900, Brazil

  • San Miguel CRS

    Lima, 32-15088, Peru

  • UCLA Vine Street Clinic

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.